Antibody-Drug Conjugates

Breaking

RAPS Euro Convergence 2026: Regulatory News - Day 1 Roundup Heart Failure 2026: Vutrisiran Data & European Pharma News Mifepristone Access Continues Under Supreme Court Hold as Planned Parenthood Responds to 5th Circuit Ruling

NewsApr 18, 2026

Salubris Biotherapeutics JK06 Shows Promise in Phase 1/2 Cancer Trial at AACR 2024

Salubris Biotherapeutics presents Phase 1/2 data for JK06, a 5T4-targeted antibody drug conjugate for advanced NSCLC and breast cancer at AACR meeting.

James Chen, PharmD

News by Topic

More News Topics

Press Releases

Analysis by Topic

More Analysis Topics

Whitepapers

Browse

By Region

Directory

By Region

For Suppliers

For Brands

Resources

Popular Topics

More Topics

Browse

About Us

Get in Touch

Quick Actions

Recent Searches

Popular Topics

Suggestions

Salubris Biotherapeutics JK06 Shows Promise in Phase 1/2 Cancer Trial at AACR 2024